Main Article Content
Background. The most important factors affecting the prognosis, tactics and results of the treatment of chronic diffuse liver diseases, comprising non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis associated with virus C (HCV), include the progression rate of fibrotic liver transformation and the fibrous tissue area. The fibrosis extent is a predictor of portal hypertension and such lethal complications as bleeding from esophagus varicose veins, acute liver failure and hepatocellular carcinoma. Materials and methods. The investigation involved 66 patients with chronic diffuse liver diseases. All the patients were divided into two groups and three subgroups. Group I consisted of patients with HCV and cirrhosis associated with hepatitis C virus; group II included patients with NAFLD. Depending on the severity of fibrosis, patients in each group were subdivided into three subgroups: no fibrosis (F0), moderate fibrosis (FI + FII), and marked fibrosis (FIII + FIV). Viral etiology of the disease was confirmed by the enzyme immunoassay analysis and PCR diagnostics. Group I consisted of 24 (57.1 %) men and 18 (42.9 %) women; the average age of patients was (45.8 ± 2.2) years. The diagnosis of NAFLD was confirmed by the results of objective examination (the presence of overweight, visceral distribution of adipose tissue), detection of insulin resistance and hyperlipidemia. Group II consisted of 8 men (33.3 %), 16 women (66.7 %); the average age was (47.3 ± 3.1) years. In all the patients the diagnosis was morphologically confirmed. The ultrasound examination of the liver in B-mode was performed, as well as shear wave elastography (SWE). Results. In 13 (19.7 %) cases (7 patients with HCV and 6 patients with NAFLD), fibrous changes of the liver were absent. 43.9 % of patients (19 patients with HCV and 10 patients with NAFLD) were diagnosed with a moderate stage of liver fibrosis, which coincided with stages 1 and 2 of fibrosis on the METAVIR scale. In 36.4 % of cases (16 patients with HCV and 8 patients with NAFLD), the stage of marked liver fibrosis was diagnosed, which coincided with stages 3 and 4 of fibrosis on the METAVIR scale. According to the ROC analysis, the SWE threshold value above which a moderate stage of HCV liver fibrosis was diagnosed proved to be 6.63 kPa (with the sensitivity of 94.7 % and the specificity of 85.7 %). In the assessment of marked fibrosis it was more than 8.81 kPa (with sensitivity of 93.7 % and specificity of 84.2 %). For NAFLD, the threshold value for moderate fibrosis was 5.56 kPa (AUC = 0.867 (95% CI 0.606 to 0.982; p < 0.001)), for marked fibrosis — more than 7.87 kPa (with the sensitivity of 87.5 % and specificity of 90.0 %). Conclusions. According to SWE results, a moderate fibrosis in patients with HCV corresponded to the value of 6.63 kPa and to 5.56 kPa for NAFLD; a marked fibrosis was diagnosed at values higher than 8.81 and 7.87 kPa for HCV and NAFLD, respectively. The SWE method has high sensitivity and specificity for staging of liver fibrosis in patients with HCV and NAFLD and may be recommended for the use in clinical practice. Introduction of SWE with the defined threshold values for liver parenchyma stiffness allows optimizing noninvasive diagnosis of fibrotic liver changes in patients with HCV and NAFLD.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Vovk EI. Nealkogol'naia zhirovaia bolezn' pecheni: rukovodstvo dlia prakticheskikh vrachei [Non-alcoholic fatty liver disease: a guide for practitioners]. Moscow: Eksmo; 2016. 160 p. (in Russian).
Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology. 2012 Jul;56(1):239-47. doi: 10.1002/hep.25610.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608. doi: 10.1016/j.jhep.2012.12.005.
Sapronova NG, Voloshin VV, Lukash YuV, Kantsurova MR, Manchenko EV, Kantsurov RN. Features of morphological study of patients with intrahepatic portal hypertension. Success of modern science and education. 2016;6(10):84-89. (in Russian).
Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8. doi: 10.1111/j.1572-0241.2002.06038.x.
Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034.
You SC, Kim KJ, Kim SU, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015 Jan 28;21(4):1158-66. doi: 10.3748/wjg.v21.i4.1158.
Ronot M, Lambert S, Wagner M, et al. Viscoelastic parameters for quantifying liver fibrosis: three-dimensional multifrequency MR elastography study on thin liver rat slices. PLoS One. 2014 Apr 10;9(4):e94679. doi: 10.1371/journal.pone.0094679.
Merchante N, Rivero-JuaÂrez A, TeÂllez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012 Jul;56(1):228-38. doi: 10.1002/hep.25616.
Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027.